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A self-assembled nanoparticle containing a photosensitizer 
and a Trojan-horse moiety (cholesterol), binds an anti-TB 
pro-drug and increases 1000-fold its activity against 
mycobacteria. These minimalist constructs will allow 
development of economically viable, efficient drug 
preparations for the treatment of drug-resistant TB 
infections. 
The recent UK Chief Medical Officers report has emphasized the 
increasing threat of antimicrobial resistance and the need for new 
strategies for control.1,2 This is particularly true for tuberculosis 
(TB). TB accounts for around 9 million new cases a year globally 
and 1.4 million deaths.3 This fact is compounded by over half a 
million cases of multi drug resistant (MDR) and extreme drug 
resistant (XDR) TB per year. The options for treating TB are limited, 
the drugs in the approved regimens were introduced in the 1960’s 
and new moieties are still in early phase testing. The cause for 
concern is that the new compounds are focused on limited targets 
and so cross-resistance is a real risk.4 Clearly, new paradigms for 
antimicrobial delivery are required. One such paradigm may rest in 
the development of soft nanoparticles as vehicles for targeted and 
controlled delivery 
In the last years the development of antimicrobials based on 
nanoparticles has attracted strong interest.5,6 For the treatment of 
Mycobacterium tuberculosis specifically, studies have so far focused 
on the sustained drug delivery properties of relatively simple 
nanoparticle preparations (mostly solid lipid and polymer based), 
using traditional drugs.7,8 However nanoparticle assemblies offer the 
possibility of introducing functionality beyond the passive release of 
the drug.9,10 The level of sophistication that can potentially be 
reached is illustrated by the “artificial organelle” approach.11 These 
approaches, although potentially very efficient, are expensive to 
develop and produce. On the other hand, a nanoparticle can be 
produced that is formed exclusively of small, uncomplicated 
molecules, each one with different functionality, but with an overall 
therapeutic effect that is larger than the sum of the individual parts. 
Here we develop a multifunctional nanoparticle that can be 
potentially applied to the treatment of TB. The nanoparticle will 
contain bacterial nutrient, a photosensitizer (PS) for photodynamic 
therapy (PDT) and an anti-TB drug.  In PDT, a PS in is activated by 
light of an appropriate wavelength producing reactive oxygen 
species that cause cell death. PDT is being used for cancer 
treatment,12 but its application to bacterial infections has been so far 
limited.13,14  
Recently, we described the synthesis and molecular recognition 
properties of very stable (CMC 11 nM), hydrophobically self-
assembled nanoparticles based on a Zn-metalloporphyrin amphiphile 
that contained also cholesterol.15 We reasoned that nanoparticles 
based on this design can be used for the targeted delivery of drugs 
that bind to the nanoparticle. Additionally, the chemistry of the 
amphiphile can be tailored in order to introduce targeting and 
enhance transport and towards photodynamic therapy (PDT) 
applications.16 For the development of an agent for the treatment of 
mycobacterium infections, we used the same amphiphilic building 
block as earlier described, but introduced Co instead of Zn as the 
metal centre, leading to amphiphile 1 (Fig. 1, Supplementary Fig. 1).  
 
Figure 1. Chemical structure of water soluble porphyrin 1R, 
amphiphilic porphyrin 1 and piyrazinoic acid ester 2, together 
with their cartoon representations 
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It is known that mycobacteria are capable of using cholesterol as an 
important carbon source during infections and during growth in 
culture 17 therefore, the presence of the cholesterol in the molecule is 
expected to provide some degree of targeting and facilitate the 
transport inside the bacterium. Co was chosen as the porphyrin metal 
centre for two reasons. First, Co metalloporphyrins are likely to be 
more efficient photosensitizers than Zn metalloporphyrins as they 
quench oxygen at a slower rate than Zn metalloporphyrins,16 
rendering a Co-porphyrin derivative a (potentially) better PDT agent. 
Second, Co-metalloporphyrins have a stronger affinity for N basic-
bearing ligands than the Zn counterparts, which will make it a more 
efficient molecular receptor to our drug model and potentially 
enhance its transport. A version of 1, unable to form nanoparticles, 
1R, was also synthesized for comparison purposes (Fig. 1, 
Supplementary Fig. 2). As a drug model we synthesized a 
hydrophobic pyrazinoic acid derivative, pyrazinoic acid hexylester 2, 
by treatment of pyrazinoic acid with oxalyl chloride followed by 
addition of hexanol (Fig. 1, Supplementary Fig. 3) 
While pyrazinoic acid is the active form of the drug,18 pyrazinoic 
acid ester 2 was selected because its hydrophobicity should make it 
bind more strongly to the nanoparticle than the free acid, and 
because ester moieties hydrolyze slowly but spontaneously in water, 
while amides typically require enzymatic assistance for the 
hydrolysis to take place in measurable timescales.19 This may lead to 
bacterial resistance as demonstrated by mycobacterium resistance to 
the prodrug pyrazinamide.20  
 
 
Figure 2. A. Cartoon representation of the nanoparticle 
assembly and the formation of the complex nanoparticle-ester 
2. B. TEM picture (negative stain) of 1 nanoparticles in the 
working buffer. The scale bar represents 20 nm. C. Variation of 
the extinction coefficient of a solution of nanoparticles upon 
addition of ester 2 (empty circles). The fitting to a binding 
model for the sequential binding of two 2 molecules per 
molecule of 1 is shown as a line for changes at 428 nm (upper 
curve) and at 415 nm (lower curve). See Supplementary Table 
1 for Kapp values and Supplementary Fig. 4B for limiting values 
of extinction coefficients. D. TEM picture (negative stain) of 
the nanoparticles in presence of 2. The scale bar represents 20 
nm 
 
Amphiphilic porphyrin 1 assembles into a nanoparticle of similar 
size and appearance to that of the previously described Zn 
derivative15 (Fig. 2A and 2B). The apparent binding affinity of 
pyrazinoic acid and the ester 2 with 1 was determined by means of 
UV titration experiments (Fig. 2C, Supplementary Fig. 4). The 
binding isotherm is consistent with the sequential binding of two 
molecules of 2 for each molecule of receptor 1. This result is in 
agreement with literature data on complexation of Co 
metalloporphyrins with amines, which show that the metal centre 
can bind two ligands.21 The apparent binding constants are 3.4x104 
M-1 and 4.5x103 M-1 for the first and second binding event 
respectively (see Materials and Methods section for details and 
Supplementary Table 1). In contrast, the binding of 2 to a cobalt 
porphyrin receptor that does not form nanoparticles show binding 
constants of 4.5x103 M-1 for the first binding event and 50 M-1 for 
the second (see Supplementary Table 1). Moreover, for the 
nanoparticle, but not for 1R, the ligand may also bind in a non-
specific manner (yielding complexes with stoichiometry larger than 
1:2) via insertion of the hydrophobic tail. The implications are that, 
upon de-assembly of the particle (for example, as the cholesterol 
moiety is metabolized into the bacteria), the drug will be more easily 
released. TEM pictures of 1 shows that the ligand increases the size 
of the nanoparticles from an average 9.5 to 12.3 nm diameter in 
presence of 2 (Figs. 2 B and D), consistent with ligand binding to the 
nanoparticle. 
 
Figure 3. A. Percentage survival of M. fortuitum 4 days after 
treatment with pure 1. Red columns represent the survival for 
non-irradiated samples and the blue columns the survival for 
samples that where irradiated 24 hours after exposure to the 
nanoparticle (75 J/cm2 energy dose). B.  Idem for samples 
treated with 1 and 2 .The ratio of concentrations [2]:[1] is 2 in 
all samples. The concentration of 2 bound to the nanoparticle is 
shown in parenthesis and has been calculated from the binding 
constants. See Supplementary Table 2 and 3 for numerical data. 
In all cases, the error bars represent twice the standard 
deviation of three measurements.  
 
Mycobacterium fortuitum was chosen as a model for in vitro bacteria 
killing experiments. M. fortuitum is a fast growing mycobacterium 
that can be manipulated under containment level 2 conditions 
making it a useful surrogate for M. tuberculosis.22 M. fortuitum was 
treated either with nanoparticle 1, ester 2 or nanoparticle 1 in 
presence of 2, at a molar ratio 2:1 drug 2/receptor 1 (see 
Supplementary Information for details). For M. fortuitum treated 
with 2 alone, a concentration up to 50 mM (8.6 mg/mL) is required 
for bacterial cell death under the conditions used in this study. Below 
these concentrations the drug does not show any effect. For these 
experiments, the addition of water soluble porphyrin 1R up to 280 
M did not have any effect on the cell survival.  For nanoparticle 1 
alone, the bacterium survival is around 40-50% when the 
concentration of the nanoparticle 35 M, going up to 60% when the 
concentration is further lowered to 17.5 M. (Fig. 3A, 
Supplementary Table 2)  
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 Irradiation of the samples with light at 430 nm (the maximum 
absorption of the nanoparticle) results on a decrease in survival of 
10-15 % in relation to not irradiated samples for all the 
concentrations tested (Fig. 3A, Supplementary Table 2). This result 
is attributed to the photosensitizer action of the metalloporpyrin 
moiety within the bacteria upon irradiation.  When treated with 
nanoparticle 1 in the presence of 2, quantitative killing takes place 
for samples 280 M in 1 (with 370 M of 2 bound to nanoparticle), 
while the survival of bacterium increases in a typical dose-dependent 
fashion as the concentrations tested decrease, up to 50% survival for 
samples with 17.5 M in 1 (with 9.5 M of 2 bound to nanoparticle). 
(Fig.3B, Supplementary Table 3). Finally, when samples treated 
with 1 in presence of 2 are also irradiated at 430 nm quantitative 
killing takes place down to concentrations of 1 35 M (with 26 M 
of 2 bound to nanoparticle), while a survival of 40% approx. is 
observed when the concentration is further lowered to 17.5 M in 1 
(with 9.5 M of 2 bound to nanoparticle). This result is consistent 
with the nanoparticle facilitating the transport of the pyrazinoic acid 
ester 2, together with the expected photosensitizer action of the 
porphyrin moiety 
Conclusions 
In summary, this work shows that the combination of a small 
molecule based nanoparticle (1) with the appropriate derivative 
of a known drug (2) results in quantitative bacterial killing for 
M. fortuitum, a widely used model for M. tuberculosis down to 
15 g/mL from 10 mg/mL for the drug 2 in absence of the 
nanoparticle (Fig. 3, Supplementary Tables 2 and 3). The 
enhancing of the drug activity in the presence of the 
nanoparticle is attributed to the ability of the nanoparticle to 
facilitate the transport of the drug into the bacteria and is 
supported by the fact that the nanoparticle on its own leads to 
bacterial killing upon irradiation. The transport activity can be 
attributed to the presence of a cholesterol moiety. Cholesterol is 
used by M. fortuitum as nutrient enabling the transport of the 
other moieties associated to it, such as drug model 2 and the 
covalently linked Co metalloporphyrin moiety. It is also 
possible that the nanoparticle components de-assemble when in 
contact with the bacterial cell wall and incorporate as individual 
molecules. Irradiation may then lead to bacterial wall damage 
resulting in enhanced drug absorption. Whatever the precise 
mechanism of action, these kinds of nanoparticles are a strong 
candidate to be developed into therapeutic agents for resilient 
strains of tuberculosis that currently require drastic treatment, 
including pulmonary surgery.23 A combined therapy based on 
the use of a system such as the one described here will offer a 
much more convenient alternative, both from the patient and 
the economic point of view. The use of UV to enhance drug 
activity will not be practical in most patients. However, in those 
with MDR and XDR TB, where treatment options are limited, 
use of an adapted bronchoscope could provide targeted UV 
delivery to the site of disease. The modular nature of the 
nanoparticles and the relative simplicity of the building blocks  
should allow us to develop related systems with different 
porperties. For example, a version bearing ergosterol may target 
fungi 24 and can be tested against post-transplant fungal 
infections. The potential toxicity of our porphyrin derivatives 
may be mitigated by developing a nanoparticle version bearing 
more biocompatible (e.g. heme derivative) moieties. The 
potential of these systems is currently being analysed in our 
labs.  
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